---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-25-000251"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:27:51.574890+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lilly Q3 revenue up 54% to $17.6B; raises FY2025 guidance on Mounjaro/Zepbound demand

## Summary
- Q3 reported EPS $6.21 vs $1.07 YoY; non-GAAP EPS $7.02 vs $1.18.
- Revenue $17.6B (up 54% YoY) driven by Mounjaro and Zepbound volume growth.
- Raises FY2025 revenue guidance to $63.0-63.5B; reported EPS $21.80-22.50, non-GAAP EPS $23.00-23.70.
- Pipeline: plans to submit orforglipron for obesity to global regulators by year-end after positive Phase 3 trials.
- U.S. FDA approved Inluriyo (imlunestrant) for advanced/metastatic breast cancer; manufacturing expansions in VA, TX, Puerto Rico.

## SEC filing metadata
- accession: 0000059478-25-000251
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947825000251/0000059478-25-000251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947825000251/lly-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-25-000251
- JSON: https://secwatch.observer/filing/0000059478-25-000251.json
- Plain text: https://secwatch.observer/filing/0000059478-25-000251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.